Beijing Konruns Pharmaceutical Co.,Ltd.

Shanghai Stock Exchange 603590.SS

Beijing Konruns Pharmaceutical Co.,Ltd. Goodwill for the year ending December 31, 2023: USD 13.75 M

Beijing Konruns Pharmaceutical Co.,Ltd. Goodwill is USD 13.75 M for the year ending December 31, 2023, a -2.80% change year over year. Goodwill is the value attributed to intangible assets, such as brand reputation or customer relationships, acquired in a business combination.

Beijing Konruns Pharmaceutical Co.,Ltd. Goodwill for the year ending December 31, 2022 was USD 14.15 M, a -7.92% change year over year.
Beijing Konruns Pharmaceutical Co.,Ltd. Goodwill for the year ending December 31, 2021 was USD 15.37 M, a 1.68% change year over year.
Beijing Konruns Pharmaceutical Co.,Ltd. Goodwill for the year ending December 31, 2020 was USD 15.11 M, a 0.00% change year over year.
Beijing Konruns Pharmaceutical Co.,Ltd. Goodwill for the year ending December 31, 2019 was USD 0.00, a 0.00% change year over year.

Key data

Date	Goodwill	Total Assets	Current Liabilities	Total Non-Current Liabilities

Shanghai Stock Exchange: 603590.SS

Beijing Konruns Pharmaceutical Co.,Ltd.

CEO	Ms. Yuping Sun
IPO Date	Sept. 3, 2018
Location	China
Headquarters	Building 3
Employees	447
Sector	Healthcare
Industries Pharmaceuticals 3D Printing Biotechnology Chemicals & Advanced Materials Clinical Trials Medical Instruments Plastics Vaccines

Description

Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research, production, and sale of various drugs in China. The company offers Su Ling product in the hemagglutinin preparation market used to reduce bleeding during surgery and control postoperative surgery. It also engages in the development of drug candidates, including CX1026, CX1003, and KC1036. The company was founded in 2003 and is headquartered in Beijing, China.

Key trends

Past 5 years